RTTNews | Dec 22, 2021 11:40AM EST

11:39 Wednesday, December 22, 2021 (RTTNews.com) - Shares of nano-cap company BiondVax Pharmaceuticals Ltd. (BVXV) nearly doubled after the biopharmaceutical company announced that it has inked definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Gttingen, Germany.

BVXV is currently trading at $2.788, up $1.308 or 88.3784%, on the Nasdaq.

The company said the agreements are part of a broader collaboration, expected to be signed in January 2022, covering development and commercialization of NanoAbs for several other disease indications with large market sizes that leverage their unique binding affinity, stability at high temperatures, and potential for more effective and convenient routes of administration.

Read the original article on RTTNews ( https://www.rttnews.com/3251166/biondvax-pharma-stock-soars-88-after-inking-agreements-for-nanosized-covid-19-antibody-therapy.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved